Home / Dermatology
Dermatology

| 3 min read
Phase 2 trial shows that a topical drug rapidly reduces malodor, pain, and improves quality of life for patients with malignant fungating wounds.


Stay connected with all of the latest from Drug Discovery News.
Subscribe